Shire stands to suffer from Genzyme plant OK; Krka's 2011 sales break €1B;

@FiercePharma: Interesting executive interview/analysis of Cipla's management tweaks, efforts to jump start exports--ET. Article | Follow @FiercePharma

> Shire ($SHPGY) faces 'significant headwinds' now that Fabry disease drug rival Genzyme has won European approval for its new Boston-area plant, an analyst said. Story

> Watson Pharmaceuticals ($WPI) launched Vestura, its generic version of Bayer's oral contraceptive Yaz. Item

> Slovenian drugmaker Krka said 2011 sales rose 6% to top €1 billion. Report

> New Irish guidelines for pharmaceuticals marketing prohibit entertaining health professionals at sporting and entertainment events. Story

> Contract manufacturer and API maker AMRI ($AMRI) won U.K. approval for its plant in Holywell, Wales, on top of a successful FDA audit last June. Article

> Brazil introduced Sanofi Pasteur's injectable polio vaccine into its national immunization program, which also includes doses of an oral polio vaccine. News

> Indian generics maker Sohm said its new nutraceuticals plant in Ahmedabad has started turning out its new line of remedies, including a probiotic anti-diarrheal, Diorac. Report

Biotech News

@FierceBiotech: Scientists balk as U.S. gov't pushes limits to bird #flu discourse. Article | Follow @FierceBiotech

@JohnCFierce: Just about everybody expected dapagliflozin to get batted down; but the rejection also spells trouble for other SGLT2 inhibitors. | Follow @JohnCFierce

@RyanMFierce: Hmm. Is it realistic for Obama to set a 2025 goal for effective ways to treat and prevent Alzheimer's? More | Follow @RyanMFierce

@FierceMedDev: Covidien gives update on voluntary recall of BIS bilateral sensors. Release | Follow @FierceMedDev

> FDA rejects dapagliflozin for diabetes, raising concerns for a class. Story

> Bristol-Myers reports interferon-free cures in small PhII hep C study. Article

Vaccines News

> Novartis' meningitis B vaccine aces study en route to market. News

> Breast cancer vaccine set for large-scale testing. Story

> Flu season gets off to a sluggish start. More

> Paragon nabs $15M filovirus vax contract from DoD. Item

> Confident Inovio chief pushes ahead on universal flu vaccine. Article

Pharma Manufacturing News

> Bioprocess budget hikes a sign of efficiency quest. Report

> Genzyme revives Fabrazyme with EMA plant OK. News

> Congresswoman: Novartis troubles call for more FDA oversight. Item

> Novartis, Lundbeck score wins for manufacturing in the West. Article

And Finally... Dementia patients in nursing homes who use antidepressants are more likely to fall, a new study found. Report

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.